In response to the ongoing opioid addiction and overdose epidemic, the U.S. Department of Health and Human Services, through the Substance Abuse and Mental Health Services Administration (SAMHSA), has rolled out a State Opioid Response (SOR) grant funding opportunity that will provide nearly $1.5 billion to states and territories.
Interoperability in healthcare, it would seem, is at an important inflection point.
Anthem announced plans to rebrand as Elevance Health back in March, but one component still needed to be finalized: shareholder approval. The insurer received that approval this week, as shareholders gave the green light to the change at its annual meeting.
Johns Hopkins Aramco Healthcare’s medical director of clinical informatics Dr. Tamara Sunbul on why clinician buy-in ensures that tech is aligned with user requirements.
The Pharmaceutical Research and Manufacturers of America has won its lawsuit against the Department of Health and Human Services challenging a portion of a final rule that required drug manufacturers to ensure that patient financial assistance is provided entirely
The Department of Health and Human Services is announcing a funding opportunity of nearly $15 million for a three-year federal grant to establish a Substance Abuse and Mental Health Services Administration (SAMHSA) program meant to strengthen behavioral healthcare for residents of nursing homes and other long-term care facilities.
When developing and implementing AI models, it’s essential to consider a range of factors, according to UW Health physician informatics director for predictive analytics Dr. Brian Patterson.
Under emergency use authorization, the U.S. Food and Drug Administration has expanded eligibility for the Pfizer-BioNTech COVID-19 booster vaccine to children 5 to 11 years old. People in that age group are now cleared for a single booster dose of the shot at least five months after they’ve completed the primary two-dose series.
Oscar Health shareholder Lorin Carpenter is suing Oscar Health CEO Mario Schlosser and others asking for class action status, claiming the insurer misled investors about the costs associated with COVID-19 when they bought Class A common stock in the company.
Employers and health insurers paid hospitals about 224% above what Medicare would have paid in 2020, according to a new RAND report comparing private insurer payments to Medicare rates.